NIHR Maudsley BRC Blog

Our latest news & events

Depression: low serotonin may not be the cause – but antidepressants still work

A recent study found inconsistent evidence linking the neurotransmitter serotonin to depression. In an article for The Conversation, the authors of the study concluded that it is impossible to say that taking SSRI antidepressants is worthwhile. But is it safe to conclude that serotonin is not involved in depression or that modern antidepressants aren’t helpful in treating the condition?

 

By NIHR Maudsley BRC at 25 Jul 2022

People with depression “stagnating” in primary care, says top UK Psychiatrist

A new study from researchers supported by the NIHR Maudsley Biomedical Research Centre has found “substantial and concerning” gaps in the level of care being provided to people with depression. It also warns that those able to access care are “stagnating” in a system that results in their illness persisting for longer than it should.

By NIHR Maudsley BRC at 11 Jul 2022

Next generation of rapid-acting antidepressants: Can ketamine help prevent suicide?

Naghmeh Nikkheslat is a Senior Research Associate at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) who is working on a project funded by the NIHR Maudsley BRC to investigate the use of ketamine as a medication for depression. In this blog, she talks about her research into depression and the immune system and what we currently know about ketamine as an anti-inflammatory antidepressant in psychiatric emergencies.

By NIHR Maudsley BRC at 10 Jan 2022

Psilocybin, in 10mg or 25mg doses, has no detrimental effects in healthy people

New research from King’s College London, in partnership with COMPASS Pathways and supported by NIHR Maudsley BRC, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants at the same time.

By NIHR Maudsley BRC at 4 Jan 2022

What is treatment-resistant depression? New report calls for clearer definition to inform research and improve treatment

A group of mental health experts from research, industry, regulatory bodies and with lived experience have proposed new agreed criteria to define the type of depression that current medications and therapies cannot treat effectively. The report aims to provide consistent definitions for future research, and especially for designing clinical trials for new medications, with the aim of helping to develop more tailored and effective treatments for people experiencing this difficult condition.

By NIHR Maudsley BRC at 15 Dec 2021